Artwork

Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

04_05 Muscle Invasive Bladder Cancer

29:16
 
Share
 

Manage episode 413590019 series 3335024
Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

1. Etymology, presentation, and work-up of bladder/urothelial cancer
2. Role of perioperative systemic therapy
3. Tri-modality therapy (bladder sparing approach)
4. Considerations for upper tract urothelial cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1. Bellmunt J et al. Lancet Oncol. 2021;22(4):525-537. doi:10.1016/S1470-2045(21)00004-8

2. Birtle AJ et al. JCO. Published online February 13, 2024. doi:10.1200/JCO.23.01659

3. Birtle A et al. Lancet. 2020;395(10232):1268-1277. doi:10.1016/S0140-6736(20)30415-3

4. Bajorin DF et al. NEJM. 2021;384(22):2102-2114. doi:10.1056/NEJMOA2034442/

5. James ND et al. NEJM. 2012;366(16):1477-1488. doi:10.1056/NEJMOA1106106/

6. Pfister C et al. JCO 2023;41(17_suppl) doi:10.1200/JCO.2023.41.17_SUPPL.LBA4507

7. Pfister C et al. Eur Urol. 2021;79(2):214-221. doi:10.1016/J.EURURO.2020.08.024

8. Grossman HB et al. NEJM. 2003;349(9):859-866. doi:10.1056/NEJMOA022148/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

45 episodes

Artwork
iconShare
 
Manage episode 413590019 series 3335024
Content provided by Talking About Tumors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Talking About Tumors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

1. Etymology, presentation, and work-up of bladder/urothelial cancer
2. Role of perioperative systemic therapy
3. Tri-modality therapy (bladder sparing approach)
4. Considerations for upper tract urothelial cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1. Bellmunt J et al. Lancet Oncol. 2021;22(4):525-537. doi:10.1016/S1470-2045(21)00004-8

2. Birtle AJ et al. JCO. Published online February 13, 2024. doi:10.1200/JCO.23.01659

3. Birtle A et al. Lancet. 2020;395(10232):1268-1277. doi:10.1016/S0140-6736(20)30415-3

4. Bajorin DF et al. NEJM. 2021;384(22):2102-2114. doi:10.1056/NEJMOA2034442/

5. James ND et al. NEJM. 2012;366(16):1477-1488. doi:10.1056/NEJMOA1106106/

6. Pfister C et al. JCO 2023;41(17_suppl) doi:10.1200/JCO.2023.41.17_SUPPL.LBA4507

7. Pfister C et al. Eur Urol. 2021;79(2):214-221. doi:10.1016/J.EURURO.2020.08.024

8. Grossman HB et al. NEJM. 2003;349(9):859-866. doi:10.1056/NEJMOA022148/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

45 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide